Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 13 June 2018
Indication(s)
- NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
- NovoMix 50 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 50 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 50 is indicated for treatment of diabetes mellitus in adults.
- NovoMix 70 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 70 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 70 is indicated for treatment of diabetes mellitus in adults.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
Cystic Fibrosis Knowledge Centre
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Related Content
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo...
Added 6 months ago
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem1)
This Phase 3 study is intended to demonstrate superiority of either Sotagliflozin High dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult patients with...
Added 7 months ago
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (PIONEER 3)
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Added 7 months ago
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (PIONEER 1)
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
Added 7 months ago
A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in subjects with...
Added 7 months ago
Chromosome 6q24-related diabetes mellitus.
Chromosome 6q24-related diabetes mellitus is the most common cause of transient neonatal diabetes (TNDM), accounting for approximately two-thirds of all TNDM cases.
Added 8 months ago
The potential effect of ultra-long insulin degludec on glycemic variability.
Despite the therapeutic advances in the treatment of diabetes, metabolic control instability due to glycemic variability (GV) is frequently observed in patients with diabetes on intensive insulin therapy and is associated with...
Added 1 year ago
Outcomes of bariatric surgery in the young: a single-institution experience caring for patients under 21 years old.
Background: Medical weight loss options are rarely successful long term in young patients. Bariatric surgery has been shown to be...
Added 2 years ago
Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
Objective: To investigate the effect of initial insulin dosage on blood glucose (BG) dynamics, β-cell protection, and oxidative stress in...
Added 2 years ago
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18.
Added 3 years ago
Type 1 diabetes in adults: diagnosis and management
This guideline covers the care and treatment of adults (aged 18 and over) with type 1 diabetes.
Added 3 years ago
ISPAD Clinical Practice Consensus Guidelines 2014
This supplement of Pediatric Diabetes is an update of the guideline chapters that were originally individually published in the journal between 2006 and 2008, and as a single compendium edition in 2009.
Added 4 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/000308 |
Orphan designation | No |
Date First Approved | 01-08-2000 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Novo Nordisk A/S |